ReviewHistory of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results
References (59)
Clinical role of HPV testing
Obstet Gynecol Clin North Am
(1996)- et al.
Where's the high-grade cervical neoplasia? The importance of the minimally abnormal Papanicolaou diagnosis
Obstet Gynecol
(1998) - et al.
Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities
Obstet Gynecol
(1995) - et al.
Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance
Am J Obstet Gynecol
(1995) - et al.
Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Pap smears
Am J Obstet Gynecol
(1998) - et al.
2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests
Am J Obstet Gynecol
(2007) Management of precursor lesions of cervical carcinoma: history, host defense, and a survey of modalities
- et al.
Postcolposcopy management strategies for patients referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study
Am J Obstet Gynecol
(2003) - et al.
Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia
Obstet Gynecol
(2001) - et al.
Human papillomavirus testing in primary cervical screening
Lancet
(1995)
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries
Vaccine
Isolation of RNA from residual BD SurePath liquid-based cytology specimens and detection of HPV E6/E7 mRNA using the PreTectt HPV-Proofer assay
J Virol Methods
Clinical performance of the APTIMA® HPV Assay for the detection of high-risk HPV and high-grade cervical lesions
J Clin Virol
Assessment of new technologies for cervical cancer screening
Lancet Oncol
Use of p16-INK4A overexpression to increase the specifi city of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial
Lancet Oncol
A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions
Proc Natl Acad Sci USA
A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer
EMBO J
Condylomatous lesions of the cervix and vagina. I. Cytologic patterns
Acta Cytol
Structure and transcription of human papillomavirus sequences in cervical carcinoma cells
Nature
Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles
Virology
A new and sensitive method of screening for human papillomavirus infection
Obstet Gynecol
Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection
Am J Obstet Gynecol
An evaluation of human papillomavirus testing as part of referral to colposcopy clinics
Obstet Gynecol
Thea 1988 Bethesda System for reporting cervical/vaginal cytologic diagnosis
J Am Med Assoc
Editorial. Evaluating the role of HPV testing for women with equivocal Papanicolaou test findings
J Am Med Assoc
ASCUS LSIL Triage Study. Design, methods and characteristics of trial participants
Acta Cytol
Comparison of HPV testing, repeat cytology, and immediate colposcopy in ASCUS triage: baseline results from a randomized trial
J Natl Cancer Inst
Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance
Am J Obstet Gynecol
2001 ASCCP-Sponsored Consensus Conference. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities
JAmMed Assoc
Cited by (66)
Immunotherapy in cervix cancer
2020, Cancer Treatment ReviewsCommercially available molecular tests for human papillomaviruses: a global overview
2020, Clinical Microbiology and InfectionCitation Excerpt :For comprehensive control, including recently announced efforts to eliminate cervical cancer, two key prevention strategies are available: vaccination against human papillomaviruses (HPVs) and effective screening programmes followed by treatment of detected precancerous and cancerous lesions [1–8].
Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening
2019, International Journal of Infectious DiseasesCitation Excerpt :As HPV cannot be cultured, current tests for HPV infection rely on the detection of viral nucleic acids in the infected region. HPV DNA analysis is conducted as an adjunctive test for all cervical cytology samples in women over 30 years of age according to current recommendations (Cox, 2009). Pap smear and HPV DNA testing are currently the methods most widely applied in screening for cervical lesions, but both methods are limited by a low specificity and lack of association with patient prognoses (Schiffman and Solomon, 2009).
Commercially available molecular tests for human papillomaviruses (HPV): 2015 update
2016, Journal of Clinical Virology